# Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]

> **NCT03555422** · PHASE3 · COMPLETED · sponsor: **Karyopharm Therapeutics Inc** · enrollment: 263 (actual)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** Selinexor
- **DRUG:** Matching placebo for selinexor

## Key facts

- **NCT ID:** NCT03555422
- **Lead sponsor:** Karyopharm Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-05
- **Primary completion:** 2022-01-22
- **Final completion:** 2025-04-03
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555422

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555422, "Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03555422. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*